“…In an oncogenicity study (Wahle et al, 1999a), Picaridin was administered dermally on the dorsal aspect of the trunk to 50 CD-1 mice/sex/dose at dose levels of 0, 50, 100, or 200 mg/kg/day on 5 consecutive days/week for 18 months. No toxicity or evidence of an oncogenic potential was observed at any dose level, up to and including the HDT of 200 mg/kg/day.…”